Reference:
[1] MANCUSI C, GRASSI G, BORGHI C, et al. Determinants of healing
among patients with coronavirus disease 2019: the results of the
SARS-RAS study of the Italian Society of Hypertension [J]. J
Hypertens, 2021, 39(2): 376-80.doi:10.1097/hjh.0000000000002666.
[2] IACCARINO G, GRASSI G, BORGHI C, et al. Age and Multimorbidity
Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of
the Italian Society of Hypertension [J]. Hypertension, 2020, 76(2):
366-72.doi:10.1161/hypertensionaha.120.15324.
[3] DUAN N, DU J, HUANG C, et al. Microbial Distribution and
Antibiotic Susceptibility of Lower Respiratory Tract Infections Patients
From Pediatric Ward, Adult Respiratory Ward, and Respiratory Intensive
Care Unit [J]. Front Microbiol, 2020, 11:
1480.doi:10.3389/fmicb.2020.01480.
[4] XIA W, CHEN Y, MEI Y, et al. Changing trend of antimicrobial
resistance among pathogens isolated from lower respiratory tract at a
university-affiliated hospital of China, 2006-2010 [J]. J Thorac
Dis, 2012, 4(3): 284-91.doi:10.3978/j.issn.2072-1439.2012.02.04.
[5] ZHOU P, YANG X L, WANG X G, et al. A pneumonia outbreak
associated with a new coronavirus of probable bat origin [J].
Nature, 2020, 579(7798): 270-3.doi:10.1038/s41586-020-2012-7.
[6] MOHAPATRA R K, DHAMA K, MISHRA S, et al. The microbiota-related
coinfections in COVID-19 patients: a real challenge [J]. Beni Suef
Univ J Basic Appl Sci, 2021, 10(1): 47.doi:10.1186/s43088-021-00134-7.
[7] ZHOU F, YU T, DU R, et al. Clinical course and risk factors for
mortality of adult inpatients with COVID-19 in Wuhan, China: a
retrospective cohort study [J]. Lancet, 2020, 395(10229):
1054-62.doi:10.1016/s0140-6736(20)30566-3.
[8] MIRZAEI R, GOODARZI P, ASADI M, et al. Bacterial co-infections
with SARS-CoV-2 [J]. IUBMB Life, 2020, 72(10):
2097-111.doi:10.1002/iub.2356.
[9] CHONG W H, SAHA B K, ANANTHAKRISHNAN R, et al. State-of-the-art
review of secondary pulmonary infections in patients with COVID-19
pneumonia [J]. Infection, 2021, 49(4):
591-605.doi:10.1007/s15010-021-01602-z.
[10] SAID K B, ALSOLAMI A, MOUSSA S, et al. COVID-19 Clinical
Profiles and Fatality Rates in Hospitalized Patients Reveal Case
Aggravation and Selective Co-Infection by Limited Gram-Negative Bacteria
[J]. Int J Environ Res Public Health, 2022,
19(9).doi:10.3390/ijerph19095270.
[11] HU L F, XU X H, LI H R, et al. Surveillance of antimicrobial
susceptibility patterns among Stenotrophomonas maltophilia isolated in
China during the 10-year period of 2005-2014 [J]. J Chemother, 2018,
30(1): 25-30.doi:10.1080/1120009x.2017.1378834.
[12] DUAN Z, QIN J, LIU Y, et al. Molecular epidemiology and risk
factors of Stenotrophomonas maltophilia infections in a Chinese teaching
hospital [J]. BMC Microbiol, 2020, 20(1):
294.doi:10.1186/s12866-020-01985-3.
[13] HAFIZ T A, ALDAWOOD E, ALBLOSHI A, et al. Stenotrophomonas
maltophilia Epidemiology, Resistance Characteristics, and Clinical
Outcomes: Understanding of the Recent Three Years’ Trends [J].
Microorganisms, 2022, 10(12).doi:10.3390/microorganisms10122506.
[14] SHARIFIPOUR E, SHAMS S, ESMKHANI M, et al. Evaluation of
bacterial co-infections of the respiratory tract in COVID-19 patients
admitted to ICU [J]. BMC Infect Dis, 2020, 20(1):
646.doi:10.1186/s12879-020-05374-z.
[15] CHEN N, ZHOU M, DONG X, et al. Epidemiological and clinical
characteristics of 99 cases of 2019 novel coronavirus pneumonia in
Wuhan, China: a descriptive study [J]. Lancet, 2020, 395(10223):
507-13.doi:10.1016/s0140-6736(20)30211-7.
[16] LI J, WANG J, YANG Y, et al. Etiology and antimicrobial
resistance of secondary bacterial infections in patients hospitalized
with COVID-19 in Wuhan, China: a retrospective analysis [J].
Antimicrob Resist Infect Control, 2020, 9(1):
153.doi:10.1186/s13756-020-00819-1.
[17] SILVA D L, LIMA C M, MAGALHãES V C R, et al. Fungal and
bacterial coinfections increase mortality of severely ill COVID-19
patients [J]. J Hosp Infect, 2021, 113:
145-54.doi:10.1016/j.jhin.2021.04.001.